Axsome Therapeutics (AXSM) Equity Average (2016 - 2026)

Axsome Therapeutics has disclosed Equity Average across 11 years of filings, most recently posting $71.4 million for Q1 2026.

• Equity Average for Q1 2026 came in at $71.4 million, up 29.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $71.4 million (up 29.63% YoY), and the FY2025 annual result was $72.7 million, down 41.41% from the prior year.
• Equity Average came in at $71.4 million for Q1 2026 at Axsome Therapeutics, down from $81.0 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $274.2 million in Q3 2023 to a low of $14.9 million in Q2 2022.
• The 5-year median for Equity Average is $86.3 million (2022), against an average of $109.9 million.
• Across the five-year window, Equity Average slumped 85.56% in 2022 and surged 1206.54% in 2023, its largest moves.
• Axsome Therapeutics' Equity Average stood at $133.5 million in 2022, then jumped by 72.52% to $230.2 million in 2023, then sank by 67.44% to $75.0 million in 2024, then increased by 8.08% to $81.0 million in 2025, then dropped by 11.81% to $71.4 million in 2026.
• The last three Equity Average figures came in at $71.4 million (Q1 2026), $81.0 million (Q4 2025), and $73.4 million (Q3 2025), per Business Quant data.